Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Pathology of Breast Cancer
share announcement

Pathology of Breast Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: closed (10 October 2023) | Viewed by 4779

Special Issue Editors

Prof. Dr. Vasiliki Zolota

E-Mail Website
Guest Editor
1. Department of Pathology, School of Medicine, University of Patras, 26504 Patras, Greece
2. Department of Pathology, University Hospital of Patras, 26504 Patras, Greece
Interests: tumor pathology; breast pathology; hematopathology; liver pathology; tumor biomarkers; cancer biology
Prof. Dr. Helen Kourea

E-Mail Website
Guest Editor
Department of Pathology, School of Medicine, University of Patras, 26504 Patra, Greece
Interests: histopathology; tumors; cancer biology; oncology diagnosis; cancer diagnostics; immunocytochemistry; cancer; biomarkers; pharmacology

Special Issue Information

Dear Colleagues,

Breast carcinoma (BC) is the most common cancer and the second leading cause of cancer death in women, accounting for 12% of all new annual cancer cases worldwide. In the past two decades, advancements in molecular techniques have contributed to an improved understanding of BC biology, significant developments in the classification of breast cancer and enrichment with new molecular subtypes that have altered the daily practice of pathology. The emerging molecular classifications of BC bring novel perspectives to the assessment of individual cases and opportunities for improved management in the era of precision medicine.

Recently, molecular studies have further illuminated the heterogeneity of BC subtypes, from the better-known biological subsets of triple-negative breast carcinoma (TNBC) and HER2-positive BC to the less published luminal BCs. Teasing out the distinct subtypes allows for novel targeted therapies to be developed and implemented under the umbrella of personalized medicine.

The prognostic and predictive utility of histopathologic parameters associated with the tumor microenvironment (TME), such as tumor-infiltrating lymphocytes (TILs), are also being elucidated, and new protocols have been devised for the pathologic assessment of BC specimens that have undergone neoadjuvant therapy.

In this Special Issue, we are interested in papers that focus on the current diagnostic approaches and developments in the pathology of BC, the surgical advancements in the management of the breast and the axilla and novelties in oncological and radiotherapeutic management that impact our practices. Original articles and systematic reviews are equally welcome.

Prof. Dr. Vasiliki Zolota
Prof. Dr. Helen Kourea
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer biomarkers
  • triple negative breast cancer
  • breast cancer carcinogenesis
  • breast cancer biology
  • pathology 

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

12 pages, 20819 KiB  
Article
Next Generation Sequencing of Reactive Stroma and Residual Breast Cancer Cells in Tumor Bed after Neoadjuvant Chemotherapy
by Zsuzsanna Varga, Ailsa Christiansen, Magdalena Lukamowicz-Rajska, Aashil A. Batavia, Adriana von Teichman, Peter Schraml and Holger Moch
Cancers 2022, 14(22), 5609; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers14225609 - 15 Nov 2022
Cited by 1 | Viewed by 1788
Abstract
Primary systemic or neoadjuvant chemotherapy of breast cancer has become a standard therapy option in locally advanced or predefined intrinsic subtypes such as triple negative or Her2 positive breast cancer. Neoadjuvant chemotherapy can result in complete pathological response without residual tumor cells (tumor [...] Read more.
Primary systemic or neoadjuvant chemotherapy of breast cancer has become a standard therapy option in locally advanced or predefined intrinsic subtypes such as triple negative or Her2 positive breast cancer. Neoadjuvant chemotherapy can result in complete pathological response without residual tumor cells (tumor bed) or partial response and non-response with different amounts of reactive stroma and residual tumor cells. The interaction between therapy regimens and tumoral driver mutations have been extensively studied, although the reactive stroma of the tumor bed received less attention. In this study, we characterized the mutational status of residual breast cancer cells and reactive tumor stroma devoid of residual tumor cells in partial or non-responders using next generation sequencing. Twenty-one post-therapeutic breast surgical specimens after neoadjuvant chemotherapy underwent pathogenic driver-mutation screening using microdissected residual breast cancer cells and in reactive stroma adjacent to tumor bed areas. In reactive stroma, no mutations could be validated. In residual breast cancer cells, mutations were detected in sixteen of twenty-one cases (76%). In nine of these twenty-one cases (43%), pathogenic driver mutations (PIK3CA, PTEN, TP53, FN1, PLAG1) were identified. Pathogenic driver-mutations are exclusively restricted to residual carcinoma cells and are absent in reactive stroma independently from intrinsic breast cancer subtypes or tumor stage. These data suggest that the absence of pathogenic mutations in a tumor bed without residual tumor cells may have prognostic implications after neoadjuvant chemotherapy. Full article
(This article belongs to the Special Issue Pathology of Breast Cancer)
►▼ Show Figures

Figure 1

Other

Jump to: Research

15 pages, 2650 KiB  
Systematic Review
Prognostic Markers of Microinvasive Breast Carcinoma: A Systematic Review and Meta-Analysis
by Andrea Ambrosini-Spaltro, Francesco Di Donato, Luca Saragoni, Gábor Cserni, Emad Rakha and Maria Pia Foschini
Cancers 2023, 15(11), 3007; https://0-doi-org.brum.beds.ac.uk/10.3390/cancers15113007 - 31 May 2023
Cited by 1 | Viewed by 2459
Abstract
(1) Background: The prognostic factors of microinvasive (≤1 mm) breast carcinoma are not completely clear. The aim of this study was to perform a systematic review and meta-analysis to clarify these factors. (2) Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses [...] Read more.
(1) Background: The prognostic factors of microinvasive (≤1 mm) breast carcinoma are not completely clear. The aim of this study was to perform a systematic review and meta-analysis to clarify these factors. (2) Methods: The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology was followed. Two databases were interrogated, PubMed and Embase, and papers in English were included to address this question. The selected studies were those that reported on female patients affected by microinvasive carcinoma, and on prognostic factors with a hazard ratio (HR) for disease-free survival (DFS) and overall survival (OS). (3) Results: In total, 618 records were identified. After removing duplicates (166), identification, and screening (336 by title and abstract alone, 116 by full text and eventual supplementary material), 5 papers were selected. Seven different meta-analyses were conducted in this study, all referring to DFS, analyzing the following prognostic factors: estrogen receptor, progesterone receptor, HER2 status, multifocality and grade of microinvasion, patient’s age, and lymph node status. Only lymph node status was associated with prognosis and DFS (total number of cases: 1528; Z = 1.94; p = 0.05). The other factors examined did not significantly affect prognosis (p > 0.05). (4) Conclusions: Positive lymph node status significantly worsens prognosis in patients with microinvasive breast carcinoma. Full article
(This article belongs to the Special Issue Pathology of Breast Cancer)
►▼ Show Figures

Graphical abstract

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop